HB8908, the STOP GAMES Act of 2026, would amend section 505(q) of the Federal Food, Drug, and Cosmetic Act to curb so-called “citizen petitions” that are filed primarily to delay FDA approval of certain drug and biologic applications. The bill focuses on applications submitted under the abbreviated pathways for drugs and biologics, including applications under FDCA section 505(b)(2) and 505(j) and Public Health Service Act section 351(k). It would allow the FDA to deny a petition at any point if the agency determines the petition was submitted mainly to delay approval or does not raise valid scientific or regulatory issues on its face.
The bill also directs FDA to consider specified factors when identifying delay-oriented petitions, such as late filing after the relevant information was known, serial or repetitive petitions, petitions filed near patent or exclusivity expiration, petitions lacking supporting data, and petitions that repeat issues already addressed by FDA. If FDA finds a petition was filed primarily to delay approval, it must refer the matter to the Federal Trade Commission. The bill further tightens petition certification language, updates timing rules for exhaustion of administrative remedies, and requires courts to dismiss certain lawsuits that bypass or untimely challenge the petition process.
In addition, HB8908 expands FDA’s reporting obligations to Congress. The agency would have to identify each petition, the petitioner, the time and resources spent, the timing relative to patent expiration, the delay caused, and, where relevant, when FDA would have acted on the underlying application absent the petition. These reporting changes are designed to increase transparency around petition use and its effect on drug approval timelines.
The bill’s impact would be to strengthen FDA’s ability to police abuse of the petition process and potentially speed approval of lower-cost generic and biosimilar products by reducing strategic delays. It would also create a clearer enforcement and reporting framework around petitions that affect competition in the pharmaceutical market, while reinforcing exhaustion and timeliness requirements for related litigation.
The general sentiment reflected by the bill’s title and structure is strongly pro-competition and pro-affordability, with an emphasis on preventing abuse of regulatory procedures to keep medicines off the market longer. No committee transcript or vote record is provided, so there is no recorded debate or roll-call history here; however, the bill’s framing suggests support from lawmakers concerned about drug pricing and opposition from parties that rely on petitioning and litigation to challenge approvals or protect branded products. The main point of contention is likely whether the bill appropriately targets abusive delay tactics without discouraging legitimate scientific or safety-based petitions and public participation in FDA decision-making.
HB8908 would amend the Federal Food, Drug, and Cosmetic Act, specifically section 505(q), by giving FDA broader authority to deny petitions that appear intended to delay approval of certain drug and biologic applications. It would also revise petition certification requirements, add factors for identifying delay tactics, require referral to the FTC in certain cases, and expand reporting to Congress on petition-related delays and resource use. The bill would affect FDA petitioners, branded and generic drug manufacturers, biosimilar applicants, and litigants challenging FDA approval decisions.
The bill is framed as an anti-abuse, pro-access measure aimed at speeding entry of affordable medicines, generics, and biosimilars. Its title and provisions indicate a generally favorable posture toward limiting strategic delay tactics in the FDA petition process. Because there are no committee transcripts or votes included, there is no direct recorded sentiment from debate or floor action, but the measure appears designed to appeal to supporters of lower drug prices and greater competition in pharmaceutical markets.
The likely controversy centers on distinguishing bad-faith delay petitions from legitimate petitions raising scientific, regulatory, or safety concerns. Supporters are likely to argue that serial, late-filed, or unsupported petitions are being used to extend market exclusivity and raise drug costs, while critics may contend that the bill could chill lawful petitioning and public input before FDA. The requirement to refer delay-motivated petitions to the FTC and the expanded dismissal rules for related lawsuits may also be viewed as strengthening enforcement at the expense of procedural flexibility.